Steve is a highly experienced Non-Executive Director in the pharmaceutical and life sciences industries. His expertise lies in fundraising and IPOs, with extensive international pharmaceutical and biotech experience, focusing specifically on business development and licensing.
The majority of his 50+ year career has been with UK-based pharmaceutical companies, or their subsidiaries, all at an early stage of development. He has held board positions in 24 companies, 10 of which as Chairman, including 12 listed companies.
Dr Chris Torrance is a scientist and entrepreneur, and is CEO of PhoreMost, an early stage drug discovery company he founded in 2015.
In 2007 Chris founded Horizon Discovery to translate advances in human genome editing into a range of commercial products and services. By 2014, when it listed on the London Stock Exchange, Horizon had become the fastest growing Biotech company in the UK. Previously, Chris was Head of Oncology and Biology at the UK Biotechnology company Vernalis PLC, where he was responsible for progressing several novel kinase oncology programs.
George has spent 13 years in investment banking, most recently as an Executive Director at Goldman Sachs. He specializes in leveraged finance and private equity transactions. George has been involved in many transactions in the healthcare industry.
In addition to general business and finance expertise he lends a highly structured and analytical approach to financial assessment and risk mitigation, and advises on the best ways for Small Pharma to finance projects.
Peter graduated from Oxford in 2003 with a first class degree in Chemistry. After completing an MSc in Molecular Medicine at UCL, Peter trained and qualified as a UK and European patent attorney specializing in pharmaceuticals. Peter founded Small Pharma Ltd in January 2015.
DIRECTOR OF RESEARCH
Marie has over 18 years’ experience as an analytical scientist and project manager in the pharmaceutical industry. Following a career as an analytical scientist and project supervisor, Marie spent 5 years as an analytical consultant. She joined Small Pharma in 2016 to lead CMC development.